Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07976016 Formulation A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | Participants will receive a single dose of PF-07976016 in up to 3 study periods. In sequence 1, participants will receive formulation A followed by formulation B. There will be 7 days between each dose as a wash out period. |
| Sequence 2 | EXPERIMENTAL | Participants will receive single doses of PF-07976016 in up to 3 study periods. In sequence 2, participants will receive formulation B followed by formulation A. There will be 7 days between each dose as a wash out period. |
| Name | Type | Description |
|---|---|---|
| PF-07976016 Formulation A | DRUG | PF-07976016; formulation A - current/reference |
| PF-07976016 Formulation B | DRUG | PF-07976016; Formulation B - new/test |
Key Inclusion Criteria: * Overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs and ECG assessments. * Willing to provide consent and follow study requirements * Total body weight \>110lbs (50kg) Key Exclusion Criteria: ...
PF-07976016 Formulation A is an investigational small molecule developed by Pfizer, Inc. It is a specific formulation of the study medicine PF-07976016 that was evaluated in a Phase 1 clinical trial in healthy adult volunteers. The trial studied how different forms of the medicine are taken up into the blood.
PF-07976016 Formulation A is made by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the developer of the PF-07976016 program and sponsored the Phase 1 study of this formulation.
PF-07976016 Formulation A is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The single Phase 1 trial of this formulation has been completed, and no trials of it are currently active.
PF-07976016 Formulation A was studied in one Phase 1 trial, NCT06670170, titled A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults. The trial enrolled 12 healthy adult volunteers in the United States and is completed.
The Phase 1 trial NCT06670170 was a controlled, randomized study that enrolled 12 healthy adult volunteers aged 18 years and older in the United States. It was not double blind, and participants were not selected based on a biomarker. The study is completed.